Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients

Background Patients with COPD often have multiple comorbidities requiring use of multiple medications, and adherence rates for maintenance COPD (mCOPD) medications are already known to be suboptimal. Presence of comorbidities in COPD patients, and use of medications used to treat those comorbidities (non-COPD medications), may have an adverse impact on adherence to mCOPD medications. Objective The objective of the study was to evaluate the association between non-adherence to mCOPD medications and non-COPD medications in COPD patients. Methods COPD patients were identified using a large administrative claims database. Selected patients were 40–89 years old and continuously enrolled for 12 months prior to and 24 months after the first identified COPD diagnosis (index date) during January 1, 2009 to December 31, 2010. Patients were required to have ≥1 prescription for a mCOPD medication within 365 days of the index date and ≥1 prescription for one of 12 non-COPD medication classes within ±30 days of the first COPD prescription. Adherence (proportion of days covered [PDC]) was measured during 365 days following the first COPD prescription. The association between non-adherence (PDC <0.8) to mCOPD and non-adherence to non-COPD medications was determined using logistic regression, controlling for baseline patient characteristics. Results A total of 14,117 patients, with a mean age of 69.9 years, met study criteria. Of these, 40.9% were males and 79.2% were non-adherent to mCOPD medications with a mean PDC of 0.47. Non-adherence to mCOPD medications was associated with non-adherence to 10 of 12 non-COPD medication classes (odds ratio 1.38–1.78, all P<0.01). Conclusion Adherence to mCOPD medications is low. Non-adherence (or adherence) to mCOPD medications is positively related to non-adherence (or adherence) to non-COPD medications, implying that the need to take medications prescribed for comorbid conditions does not adversely impact adherence to mCOPD medications.

[1]  J. George,et al.  Factors associated with medication nonadherence in patients with COPD: Chest 2005;128:3198–204 , 2006 .

[2]  S. Leslie.  Using Arrays to Calculate Medication Utilization , 2005 .

[3]  J. Priest,et al.  Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. , 2011, Population health management.

[4]  H. Dastani,et al.  The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. , 2008, Respiratory medicine.

[5]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[6]  A. Swensen,et al.  The Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease and Exacerbation Definition: A Review , 2010, COPD.

[7]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[8]  E. Rönmark,et al.  The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.

[9]  Maria G. Tanzi.  Counseling to enhance medication adherence , 2012 .

[10]  J. Benner,et al.  Comparing Adherence and Persistence Across 6 Chronic Medication Classes , 2009, Journal of managed care pharmacy : JMCP.

[11]  B. Make,et al.  Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients , 2012, International journal of chronic obstructive pulmonary disease.

[12]  Jiaquan Xu,et al.  Deaths: preliminary data for 2008. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[13]  L. Ring,et al.  Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10‐year period , 2007, Journal of clinical pharmacy and therapeutics.

[14]  J. Farley,et al.  A comparison of comorbidity measurements to predict healthcare expenditures. , 2006, The American journal of managed care.

[15]  A Keskinaslan,et al.  The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review , 2007, International journal of clinical practice.

[16]  E. Ford,et al.  Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. , 2015, Chest.